6 recruiting, 5 active not recruiting, 4 completed, 1 terminated. 13 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Active not recruiting 4, Completed 3, Terminated 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Myelodysplastic Syndrome With Excess Blasts: new trials by email Literature Review of Myelodysplastic Syndrome With Excess Blasts trials Research Report on Myelodysplastic Syndrome With Excess Blasts
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-10-16 |
| A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098 - Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 | Recruiting | Apollo Therapeutics Ltd | 100 | 2024-06-04 | 2026-06-01 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2023-06-27 | 2026-08-19 |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2022-10-06 | 2025-01-01 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Dilanubicel, Cyclophosphamide, Fludarabine - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 31 | 2022-05-10 | 2026-07-10 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Azacitidine, Enasidenib, Quality-of-Life Assessment - Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 63 | 2018-01-17 | 2026-09-04 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-07-30 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Azacitidine, Laboratory Biomarker Analysis, Lenalidomide - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 282 | 2012-03-01 | 2026-09-09 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cytarabine, Decitabine, Filgrastim-sndz - Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 270 | 2007-04-04 | 2026-10-07 |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study - Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 135 | 2006-11-22 | 2026-08-07 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 144 | 2004-08-18 | 2026-07-14 |
Anemia, Refractory, with Excess of Blasts (16) · Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (9) · Leukemia, Myelomonocytic, Chronic (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Biphenotypic, Acute (6) · Leukemia, Erythroblastic, Acute (4) · Leukemia, Megakaryoblastic, Acute (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Hematologic Neoplasms (3) · Leukemia, Monocytic, Acute (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myelomonocytic, Acute (3) · Lymphoma, Non-Hodgkin (3) · Anemia, Refractory (2)
Anemia (16) · Bone Marrow Diseases (16) · Hematologic Diseases (16) · Hemic and Lymphatic Diseases (16) · Leukemia (16) · Leukemia, Myeloid (16) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Anemia, Refractory (14) · Chronic Disease (11) · Disease Attributes (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Myeloproliferative Disorders (8) · Immune System Diseases (7)
Whole-Body Irradiation (7) · fludarabine phosphate (7) · Cyclophosphamide (6) · Azacitidine (5) · Cord Blood Stem Cell Transplantation (4) · Mycophenolic Acid (4) · Tacrolimus (4) · Antilymphocyte Serum (3) · Biopsy (3) · Busulfan (3) · Peripheral Blood Stem Cell Transplantation (3) · Thiotepa (3) · fludarabine (3) · CT-P10 (2) · Clofarabine (2)
National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (5) · M.D. Anderson Cancer Center (4) · Apollo Therapeutics Ltd (1)
United States (15) · Canada (3) · Australia (1) · Israel (1) · Peru (1) · United Kingdom (1)
Filippo Milano (2) · Amanda Olson (1) · Brenda M. Sandmaier (1) · Courtney DiNardo (1) · Guillaume Richard-Carpentier (1) · Jayastu Senapati (1) · Lewis R Silverman (1) · Marie Bleakley (1) · Mikkael A Sekeres (1) · Phuong Vo (1) · Ravi Vij (1) · Rory M Shallis (1) · Sanjay Aggarwal, MD (1) · Selina Luger (1) · Warren Fingrut, MD (1)
PMID 29618479, PMID 30335787, PMID 31212080, PMID 35007144, PMID 35973199
P01CA078902 (2), P30CA015704 (2), N01CM17103 (1), N01CM62204 (1), P01CA018029 (1), P30CA013330 (1), P30CA016672 (1), P50HL110787 (1), R01CA211044 (1), R01HL121568 (1), R34HL142322 (1), U10CA021115 (1), U10CA031946 (1), U10CA032102 (1), U10CA180820 (1)